$VCEL

MCLAUGHLIN KEVIN F sold $312K of VCEL

MCLAUGHLIN KEVIN F sold 7,000 shares of Vericel Corp (VCEL) at $44.53 ($0.31M total) on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MCLAUGHLIN KEVIN F
Published Aug 14, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VCEL
Neutral
high confidence
Mentioned
$VCEL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VCELNeutralLow
01

Why it matters

The newest fact is the specific sale size (7,000 shares), price ($44.53), and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may log the sale as a sentiment datapoint, but the planned nature of the trade limits actionable signal.

03

What to watch

The article provides no context on total insider holdings beyond the post-transaction figure, nor any concurrent company-specific catalyst (earnings, trial, guidance).

Relevance 3/10Novelty 3/10Timing: Filed after-hours on 2026-08-14, covering a sale dated 2026-08-12.

Background

The article is a SEC Form 4 insider transaction disclosure for Vericel Corp, reported by a director.

Company-level read

Ticker impact

$VCELNeutralHigh confidence
Context

Vericel director Kevin F. McLaughlin sold 7,000 shares in an open-market transaction at $44.53 on 2026-08-12 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, but it explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a single planned insider sale at this scale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with management’s view of near-term risk, so traders may still watch for follow-on disclosures.

Key entities

  • Vericel Corp

    Subject of the Form 4 insider sale disclosure.

  • Kevin F. McLaughlin

    Director who sold 7,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDWDHighAI 8/10

Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD)

MediWound (MDWD) received a $3.3M award from the U.S. Department of War to develop a room-temperature-stable version of its burn treatment gel, NexoBrid. The total program budget now stands at $21.8M. NexoBrid is FDA-approved and supported by a $197M BARDA contract with Vericel (VCEL). MediWound's market cap is approximately $170M.

$VCELMedAI 8/10

Vericel Q2 Earnings Call Highlights

Vericel (NASDAQ: VCEL) reported Q2 earnings call updates. Burn Care revenue rose 22% to about $12M, with Epicel at $10.4M and NexoBrid above $1.5M. 2026 guidance was raised to $330M-$340M total revenue, MACI to $284M-$290M, Burn Care to $46M-$50M, and Q3 revenue to $76.5M-$78.5M. Board authorized a $200M buyback.

$VCELHigh

Vericel Corp (VCEL): Results of Operations and Financial Condition

Vericel Corp (VCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vericel Corporation 25 Blue Sky Drive Burlington, MA 01803 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program Total Revenue Increased 22% to $77.